Marshall Glesby is an Infectious Disease physician. ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
525 E 68th St
Baker 24
New York, NY 100214870
Telephone
212-746-7134Provider last certified this registry record 6 Jul 2023.
Clinical trials
- Doxycycline for Emphysema in People Living With HIV (The DEPTH Trial)
Sponsor: Weill Medical College of Cornell University
- Doxycycline for COPD in HIV-Infected Patients
Sponsor: Weill Medical College of Cornell University
- Pioglitazone Before Peginterferon and Ribavirin for Hepatitis C Infection in HIV/HCV-Coinfected Patients With Insulin Resistance
Sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Regeneron Pharmaceuticals, Inc.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
43.1%Statin16.4%Atorvastatin Calcium71%Rosuvastatin Calcium29%Part D<11 patientsCalcium channel blocker10.1%Amlodipine Besylate100%Part D<11 patients+ 3 more classes in this area
Anti-infectives
42.5%Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor19.5%Tivicay100%Part D<11 patientsHuman Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor9.7%Descovy100%Part D<11 patients+ 2 more classes in this area
Nervous system
11%Opioid Agonist7.5%Oxycodone Hcl50%Morphine Sulfate Er50%Part D<11 patientsBenzodiazepine related drugs3.5%Eszopiclone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
7 NIH research awards on record, funded 2004–2024 per NIH RePORTER. The latest:
- 1/2 Doxycycline for Emphysema in People Living with HIV: The DEPTH Trial
Weill Medical Coll of Cornell Univ
FY2024$1,259,310UH3HL154944 - 1/2 Doxycycline for Emphysema in People Living with HIV: The DEPTH Trial
Weill Medical Coll of Cornell Univ
FY2023$2,092,028UH3HL154944 - 1/2 Doxycycline for Emphysema in People Living with HIV: The DEPTH Trial
Weill Medical Coll of Cornell Univ
FY2022$2,133,382UH3HL154944
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Yousef Khader
Jordan University of Science and Technology
Andrew Rambaut
University of Edinburgh
Olayinka Stephen Ilesanmi
University College Hospital
Maysaa El Sayed Zaki
Mansoura University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”